Ovid begins randomisation in Phase Ib/IIa trial of epilepsy drug
Ovid Therapeutics has begun patient randomisation in a Phase Ib/IIa clinical trial of TAK-935 (OV935) to treat adults with rare epilepsies.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Epilepsy